{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:54:07Z","timestamp":1793213647444,"version":"4.5.0"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Adoptive cell therapy (ACT) has emerged as a transformative strategy in cancer immunotherapy, offering durable clinical benefit in hematologic malignancies and expanding therapeutic potential in solid tumors. However, the translation of ACT to solid malignancies remains constrained by biological, immunological, and logistical challenges. This narrative review provides an evidence based overview of the current clinical landscape of ACT in solid tumors, with a focus on chimeric antigen receptor T cell (CAR-T), tumor-infiltrating lymphocyte (TIL), and T cell receptor\u2013engineered T cell (TCR-T) therapies. We summarize recent clinical trial outcomes, highlight tumor-specific antigen targets, and examine key determinants of therapeutic efficacy across major solid tumor types. The review discusses central obstacles limiting ACT success in solid tumors, including antigen heterogeneity, immune evasion, inadequate T cell trafficking, limited persistence, and functional exhaustion within the immunosuppressive tumor microenvironment. Mechanisms driving treatment resistance, on-target off-tumor toxicity, and immune-related adverse events such as cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome are critically evaluated. We further examine evolving strategies designed to overcome these barriers, including multi-antigen targeting, armored and logic-gated CAR designs, metabolic and cytokine engineering, locoregional delivery approaches, and next-generation manufacturing platforms incorporating allogeneic and gene-edited products. In parallel, the role of biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to optimize patient stratification and enhance therapeutic outcomes. Advances in translational research, combination immunotherapy, and precision immuno-oncology are positioned as key drivers of the next phase of ACT development. By integrating mechanistic insights with emerging clinical evidence, this review outlines the progress, limitations, and future directions of ACT in solid tumors. It aims to provide a forward-looking framework to guide ongoing research, clinical trial design, and the rational implementation of adoptive cellular immunotherapies in solid malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1800292","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:26:24Z","timestamp":1778732784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Adoptive cell therapies in solid tumors: current clinical landscape, challenges, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Joe","family":"Rizkallah","sequence":"first","affiliation":[{"name":"Department of Diagnostic Radiology, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa El Deen","family":"Wehbeh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Wassouf","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Salameh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Johns Hopkins University","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Joumaa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois Jose","family":"Haddad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Saint-Joseph University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Hamade","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada M.","family":"Bakri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Awada","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Kreidieh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut","place":["Beirut, Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125524","article-title":"Cell-based therapies for solid tumors: challenges and advances","volume":"26","author":"Smolarska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2290356","article-title":"Autologous engineered T cell receptor therapy in advanced cancer","volume":"19","author":"Tsimberidou","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-025-02411-w","article-title":"Advances and obstacles of T cell-based immunotherapy in gynecological Malignancies","volume":"24","author":"Zhao","year":"2025","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Ralpha2 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01924-1","article-title":"A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer","volume":"20","author":"Zhao","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102301","article-title":"Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer","volume":"6","author":"Aznar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12967-025-06853-0","article-title":"Glutamine-driven metabolic reprogramming promotes CAR-T cell function through mTOR-SREBP2 mediated HMGCS1 upregulation in ovarian cancer","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009667","article-title":"New developments in immunotherapy for SCLC","volume":"13","author":"Dolkar","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051414","article-title":"CAR T cell therapy in glioblastoma: overcoming challenges related to antigen expression","volume":"15","author":"Luksik","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211\u201301 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.3040","article-title":"EVEREST-2: Initial data of the logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy A2B694 for patients with solid tumors associated with mesothelin (MSLN) expression and with human leukocyte antigen (HLA) loss of heterozygosity (LOH)","volume":"43","author":"Punekar","year":"2025","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-sitc2025.0535","article-title":"535 EVEREST-2: a phase 1\/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results","volume":"13","author":"Ward","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0880","article-title":"FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti\u2013PD-1\u2013based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12916-021-02006-4","article-title":"Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors","volume":"19","author":"Wang","year":"2021","journal-title":"BMC Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-023-09376-2","article-title":"Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis","volume":"71","author":"Qayoom","year":"2023","journal-title":"Immunol Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.690499","article-title":"Cell therapy with TILs: training and taming T cells to fight cancer","volume":"12","author":"Kumar","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0257-5","article-title":"Tumor-infiltrating lymphocytes in melanoma","volume":"14","author":"Lee","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1922","article-title":"Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future","volume":"29","author":"Betof Warner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf259","article-title":"Efficient expansion of tumor-infiltrating lymphocytes from gynecologic cancer","volume":"214","author":"Matsukawa","year":"2025","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-8979-9_7","article-title":"Expansion of tumor-infiltrating lymphocytes from melanoma tumors","volume-title":"Immune checkpoint blockade: methods and protocols","author":"Wickstr\u00f6m","year":"2019"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010207","article-title":"Art of TIL immunotherapy: SITC\u2019s perspective on demystifying a complex treatment","volume":"13","author":"Turcotte","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2064711","article-title":"Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions","volume":"22","author":"Granh\u00f8j","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011734","article-title":"Tumor-infiltrating lymphocyte immunotherapy comes of age: a journey of development in the Surgery Branch, NCI","volume":"13","author":"Goff","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1171","article-title":"Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma","volume":"27","author":"Seitter","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.723","article-title":"Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis","volume":"35","author":"Mart\u00edn-Lluesma","year":"2024","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40257-025-00957-5","article-title":"Tumor-infiltrating lymphocyte therapy for the treatment of metastatic melanoma","volume":"26","author":"Tsai","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524842","article-title":"Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000040845","article-title":"Lymphocyte infiltration in breast cancer: a promising prognostic indicator","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf090","article-title":"Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial","volume":"112","author":"Tas","year":"2025","journal-title":"Br J Surg"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz195","article-title":"Cytologic evaluation of tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"153","author":"Monaco","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1664","article-title":"A new approach to simplifying and harmonizing cancer clinical trials\u2014standardizing eligibility criteria","volume":"8","author":"Gerber","year":"2022","journal-title":"JAMA Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115589","article-title":"Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)","volume":"225","author":"Iannantuono","year":"2025","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02633-5","article-title":"Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer","volume":"69","author":"Lee","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02119-4","article-title":"Tumour-infiltrating lymphocytes: from prognosis to treatment selection","volume":"128","author":"Brummel","year":"2023","journal-title":"Br J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2023.2228991","article-title":"Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study","volume":"62","author":"Zhang","year":"2023","journal-title":"Acta Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2024.2392898","article-title":"Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products","volume":"13","author":"Castenmiller","year":"2024","journal-title":"Oncoimmunology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00984-x","article-title":"Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach","volume":"22","author":"Lopez de Rodas","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2006.12.006","article-title":"Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy","volume":"28","author":"Engels","year":"2007","journal-title":"Mol Aspects Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061485","article-title":"Engineering strategies to enhance TCR-based adoptive T cell therapy","volume":"9","author":"Rath","year":"2020","journal-title":"Cells"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1891\/9780826148537.0025","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.33696\/cancerimmunol.6.080","article-title":"Enhancing the efficacy of CAR-T cell therapy: a comprehensive exploration of cellular strategies and molecular dynamics","volume":"6","author":"Baysal","year":"2024","journal-title":"J Cancer Immunol (Wilmington)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/srep18851","article-title":"Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy","volume":"6","author":"Raman","year":"2016","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-020-01416-3","article-title":"Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia","volume":"37","author":"Hashem Boroojerdi","year":"2020","journal-title":"Med Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/07388551.2021.1988509","article-title":"Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic","volume":"42","author":"Safarzadeh Kozani","year":"2022","journal-title":"Crit Rev Biotechnol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00367","article-title":"The tumor vascular endothelium as decision maker in cancer therapy","volume":"8","author":"Klein","year":"2018","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.811","article-title":"Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma","volume":"181","author":"Piali","year":"1995","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v88.2.667.bloodjournal882667","article-title":"Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium","volume":"88","author":"Griffioen","year":"1996","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100383","article-title":"Deciphering the tumour immune microenvironment cell by cell","volume":"18","author":"Nabhan","year":"2023","journal-title":"Immuno-Oncology Technol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B87","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ni1536","article-title":"CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation\u2013mediated apoptosis of effector CD4+ T cells","volume":"8","author":"Pandiyan","year":"2007","journal-title":"Nat Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1172\/jci80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031856","article-title":"l-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"Rodriguez","year":"2007","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00127","article-title":"Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues","volume":"5","author":"Van Overmeire","year":"2014","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.007","article-title":"Macrophages: obligate partners for tumor cell migration, invasion, and metastasis","volume":"124","author":"Condeelis","year":"2006","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02361-5","article-title":"Reduced CTL motility and activity in avascular tumor areas","volume":"68","author":"Manaster","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218363","article-title":"Lactic acid and an acidic tumor microenvironment suppress anticancer immunity","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-0558","article-title":"TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti\u2013PD-1 response in follicular lymphoma","volume":"26","author":"Yang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2019.07.002","article-title":"Regulatory mechanisms of inhibitory immune checkpoint receptors expression","volume":"29","author":"Curdy","year":"2019","journal-title":"Trends Cell Biol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065x.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B109","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signaling"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of PD-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-15-1347","article-title":"TGF\u03b21-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer","volume":"6","author":"Park","year":"2016","journal-title":"Cancer Discov"},{"key":"B112","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-0890","article-title":"Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","article-title":"Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma","volume":"5","author":"Schmidts","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1172\/jci131246","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512317","article-title":"CRISPR\/Cas9: a powerful strategy to improve CAR-T cell persistence","volume":"24","author":"Wei","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","article-title":"Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker","volume":"15","author":"Martins","year":"2024","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1172\/jci163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114358","article-title":"Advances in modular control of CAR-T therapy with adapter-mediated CARs","volume":"187","author":"McCue","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1995.6.6-813","article-title":"Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation","volume":"6","author":"Bordignon","year":"1995","journal-title":"Hum Gene Ther"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-20-0470","article-title":"Rationally designed transgene-encoded cell-surface polypeptide tag for multiplexed programming of CAR T-cell synthetic outputs","volume":"9","author":"Johnson","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic Notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol Cancer"},{"key":"B134","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40164-024-00570-y","article-title":"CRISPR\/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications","volume":"13","author":"Feng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01282-8","article-title":"Ablation of FAS confers allogeneic CD3(-) CAR T cells with resistance to rejection by T cells and natural killer cells","volume":"8","author":"Menegatti","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B140","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","article-title":"Management of cytokine release syndrome (CRS) following CAR T-cell therapy: a comprehensive review","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin Cancer Bull"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578717","article-title":"Neurotoxicity associated with chimeric antigen receptor T-cell therapy","volume":"407","author":"Wronski","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3738","article-title":"Assessment of pretreatment and posttreatment evolution of neurofilament light chain levels in patients who develop immune effector cell-associated neurotoxicity syndrome","volume":"8","author":"Butt","year":"2022","journal-title":"JAMA Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01618","article-title":"Adoptive cell therapy for nonhematologic solid tumors","volume":"41","author":"Olson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01509-2","article-title":"Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery","volume":"10","author":"Murad","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00669-y","article-title":"Prospects of synergy: Local interventions and CAR T cell therapy in solid tumors","volume":"38","author":"Holtermann","year":"2024","journal-title":"BioDrugs"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603792","article-title":"Adoptive cell therapy for cancer: Combination strategies and biomarkers","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800292\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:26:32Z","timestamp":1778732792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800292\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":151,"alternative-id":["10.3389\/fimmu.2026.1800292"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800292","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1800292"}}